FDA approves expanded indication for Ozurdex implant

The U.S. Food and Drug Administration has approved Ozurdex for the general patient population being treated for diabetic macular edema, Allergan announced in a press release.In June, the FDA approved Ozurdex (dexamethasone intravitreal implant 0.7 mg) for the treatment of DME in pseudophakic adult patients or patients who were scheduled for cataract surgery.